SCHEMBL75592

SCHEMBL75592

COC(=O)C(N)(c1ccccn1)C1CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.41
HSD17B10 Q99714 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
ALDH1A1 P00352 1/20 0.37
CASP1 P29466 1/20 0.37
CHRM2 P08172 2/20 0.37
CHRM3 P20309 2/20 0.37
CNR1 P21554 1/20 0.36
CNR2 P34972 1/20 0.36
CYP19A1 P11511 1/20 0.36
KCNN4 O15554 1/20 0.36
ADORA2A P29274 1/20 0.35
MEN1 O00255 4/20 0.35
KMT2A Q03164 4/20 0.35
AHR P35869 1/20 0.35
PLCG1 P19174 1/20 0.35
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
HPGD P15428 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL75349 0.77 KCNN4 (0.53) ALDH1A1CHRM2CHRM3KCNN4MEN1
SCHEMBL5700780 0.77 SMN1; SMN2 (0.44) KDM4EHSD17B10SMN1; SMN2L3MBTL1ALDH1A1
SCHEMBL504847 0.73 PLCG1 (0.51) KDM4ESMN1; SMN2L3MBTL1ALDH1A1CYP19A1
SCHEMBL28403522 0.73 SMN1; SMN2 (0.47) KDM4EHSD17B10SMN1; SMN2L3MBTL1ALDH1A1
SCHEMBL9978324 0.72 SMN1; SMN2 (0.46) KDM4ESMN1; SMN2L3MBTL1ALDH1A1KCNN4
SCHEMBL10334728 0.72 SMN1; SMN2 (0.46) KDM4ESMN1; SMN2L3MBTL1ALDH1A1KCNN4
SCHEMBL20166133 0.72 AHR (0.47) KDM4ESMN1; SMN2L3MBTL1ALDH1A1KCNN4
SCHEMBL11001068 0.72 SMN1; SMN2 (0.50) KDM4ESMN1; SMN2L3MBTL1ALDH1A1KCNN4
SCHEMBL2674710 0.72 SMN1; SMN2 (0.44) KDM4ESMN1; SMN2L3MBTL1ALDH1A1CHRM2
SCHEMBL1027526 0.71 AHR (0.46) KDM4ESMN1; SMN2L3MBTL1KCNN4ADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8129423-B2 1-Adamantan-2-yl-3-benzyl-1,3-dihydro-imidazol-2-one; 11beta-hydroxysteroid dehydrogenases (11beta-HSD) inhibitor; antidiabetic, hypotensive, hypoglycemic agent; resist hyperglycemia provoked by obesity or stress; HOFFMAN-LA ROCHE INC. (US) 2012-03-06 US disclosed
EP-2308851-A1 Imidazolone and imidazolidinone derivatives as 11B-HSD1 inhibitors for the treatment of diabetes F. Hoffmann-La Roche AG (CH) 2011-04-13 EP disclosed
EP-2104665-A2 IMIDAZOLONE AND IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS FOR DIABETES F. Hoffmann-Roche AG (CH) 2009-09-30 EP disclosed
US-20080103183-A1 NEW IMIDAZOLONE AND IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS HOFFMANN-LA ROCHE INC. 2008-05-01 US disclosed
WO-2008046758-A2 IMIDAZOLONE AND IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS FOR DIABETES F. HOFFMANN-LA ROCHE AG (CH) 2008-04-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080103183-A1 NEW IMIDAZOLONE AND IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS HSD11B1, HSD17B1, HSD17B11 KDM4E 1757/4885HSD17B10 22/4885SMN1; SMN2 1998/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.